Patents by Inventor James H. Doroshow

James H. Doroshow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use
    Patent number: 9644037
    Abstract: Monoclonal antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 (pT1989 ATR), antigen binding fragments, conjugates thereof, and the use of these antibodies, antigen binding fragments and conjugates are disclosed herein. Also disclosed are nucleic acids encoding these antibodies, vectors including these antibodies, and isolated host cells transformed with these nucleic acids and vectors. Methods are also disclosed for using these antibodies, such as to detect pT1989 ATR, or to determine the dose of an agent of use to treat a subject. The antibodies are also of use for identifying ATR inhibitors.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: May 9, 2017
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Thomas D. Pfister, Allison M. Marrero, Ralph E. Parchment, James H. Doroshow, Robert J. Kinders
  • ANTIBODIES THAT SPECIFICALLY BIND ATAXIA TELANGIECTASIA-MUTATED AND RAD3-RELATED KINASE PHOSPHORYLATED AT POSITION 1989 AND THEIR USE
    Publication number: 20160251447
    Abstract: Monoclonal antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 (pT1989 ATR), antigen binding fragments, conjugates thereof, and the use of these antibodies, antigen binding fragments and conjugates are disclosed herein. Also disclosed are nucleic acids encoding these antibodies, vectors including these antibodies, and isolated host cells transformed with these nucleic acids and vectors. Methods are also disclosed for using these antibodies, such as to detect pT1989 ATR, or to determine the dose of an agent of use to treat a subject. The antibodies are also of use for identifying ATR inhibitors.
    Type: Application
    Filed: October 8, 2014
    Publication date: September 1, 2016
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human...
    Inventors: Thomas D. Pfister, Allison M. Marrero, Ralph E. Parchment, James H. Doroshow
  • Mice with combined disruption of Gpx1 and Gpx2 genes have growth retardation, hypothermia, and colitis and provide a mouse model for cancer
    Patent number: 6762343
    Abstract: Disclosed is a transgenic knockout mouse whose genome has a homozygous disruption in its endogenous Gpx1 and Gpx2 genes, wherein the disruptions result in a decrease in GPX activity in the transgenic mice when compared to non transgenic mice of the same type. Methods for production of the mouse are presented. Also disclosed are cells derived from the transgenic knockout mouse. The invention further provides a mouse model for the disorders of ileitis, colitis,inflammatory bowel disease, ileal cancer and myeloleukemia. The mouse can be used in a method for identifying therapeutic agents for the treatment of an individual diagnosed with one or more of said disorders.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: July 13, 2004
    Assignee: City of Hope
    Inventors: Fong-Fong Chu, Robert S. Esworthy, James H. Doroshow
  • Mice with combined disruption of Gpx1 and Gpx2 genes have growth retardation, hypothermia, and colitis and provide a mouse model for cancer
    Publication number: 20030009776
    Abstract: Disclosed is a transgenic knockout mouse whose genome has a homozygous disruption in its endogenous Gpx1 and Gpx2 genes, wherein the disruptions result in a decrease in GPX activity in the transgenic mice when compared to non transgenic mice of the same type. Methods for production of the mouse are presented. Also disclosed are cells derived from the transgenic knockout mouse. The invention further provides a mouse model for the disorders of ileitis, colitis,inflammatory bowel disease, ileal cancer and myeloleukemia. The mouse can be used in a method for identifying therapeutic agents for the treatment of an individual diagnosed with one or more of said disorders.
    Type: Application
    Filed: February 28, 2002
    Publication date: January 9, 2003
    Inventors: Fong-Fong Chu, Robert S. Esworthy, James H. Doroshow
  • Blockade of taxane metabolism
    Publication number: 20010041706
    Abstract: The present invention relates to methods of inhibiting taxane metabolism in patients receiving taxane treatment, in which an effective amount of a CYP3A4 inhibitor and a CYP2C8 inhibitor are administered to the patient.
    Type: Application
    Filed: March 22, 2001
    Publication date: November 15, 2001
    Inventors: Timothy W. Synold, James H. Doroshow
  • N-Acetyl-cysteine protects against cardiac damage from subsequently-administered cardio-toxic anthra-cycline in cancer therapy
    Patent number: 4331648
    Abstract: The cardiac damage, occurring after treatment with an anthracycline, such as adriamycin, is prevented when N-acetyl-cysteine is orally administered about one hour prior to the treatment with the anthracycline.
    Type: Grant
    Filed: September 23, 1980
    Date of Patent: May 25, 1982
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Charles E. Myers, Jr., James H. Doroshow, Gershon Y. Locker